Research Article
Does Fatigue Complaint Reflect Memory Impairment in Multiple Sclerosis?
Table 1
Clinical and demographic characteristics of MS patients.
| | | MS patients () |
| | Females (%) | 37 (74) | | Males, (%) | 13 (26 ) | | Education level, mean years ± SD | 12 ± 2 | | Professional activity, (%) | 23 (46) | | MS form, (%) | | | RR | 35 (70) | | PP | 10 (20) | | SP | 5 (10) | | Disease duration, mean years, ± SD | 13 ± 8 | | EDSS score, median (IQR) (25–75) | 3.0 (2.0–5.0) | | MS treatments, (%) | | | No treatment | 16 (32) | | Injectable immunomodulators | 15 (30) | | Natalizumab | 12 (24) | | Other immunosuppressants | 7 (14) | | Concomitant treatments, (%) | | | Benzodiazepine | 11 (22) | | Antidepressant | 12 (24) | | Hypnotic | 1 (2) | | Antiepileptic | 11 (22) | | BDI-II score, median (IQR) (25–75) | 14.5 (10–26) | | Depressive state, (%) | | | Minimal | 9 (18) | | Slight | 20 (40) | | Moderate | 10 (20) | | High | 11 (22) |
|
|
BDI-II: Beck Depression Inventory; EDSS: Expanded Disability Status Scale; IQR: interquartile range; : number of patients; MS: multiple sclerosis; RR: relapsing remitting; PP: primary progressive; SD: standard deviation; SP: secondary progressive.
|
